Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$516K Buy
1,466
+125
+9% +$44.6K 0.17% 130
2025
Q4
$439K Sell
1,341
-81
-6% -$25.7K 0.15% 148
2025
Q3
$401K Buy
1,422
+28
+2% +$8.12K 0.14% 151
2025
Q2
$389K Buy
1,394
+132
+10% +$37.4K 0.15% 137
2025
Q1
$393K Sell
1,262
-42
-3% -$12.4K 0.21% 93
2024
Q4
$340K Buy
1,304
+288
+28% +$85.4K 0.17% 115
2024
Q3
$327K Sell
1,016
-155
-13% -$50.7K 0.27% 96
2024
Q2
$366K Sell
1,171
-37
-3% -$10.9K 0.24% 89
2024
Q1
$343K Sell
1,208
-101
-8% -$29.6K 0.38% 83
2023
Q4
$377K Buy
+1,309
New +$357K 0.48% 62

Other funds holding AMGN

Sunpointe's AMGN Position: Q1 2026 in Review

Sunpointe increased its Amgen (AMGN) stake by 9.3% in Q1 2026, buying an estimated $44.6K and bringing the position to 1,466 shares worth $516K. The position accounts for 0.17% of the portfolio, ranked #130.

Sunpointe first reported a position in AMGN in Q4 2023 and has held it in 10 quarters since. 3,126 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

  • Sunpointe held 1,466 shares of Amgen worth $516K as of Q1 2026.
  • Sunpointe bought 125 Amgen shares in Q1 2026, an estimated $44.6K.
  • Amgen made up 0.17% of Sunpointe's portfolio in Q1 2026, its #130 holding.
  • Sunpointe first reported a position in Amgen in Q4 2023 and has held it in 10 quarters since.
  • 3,126 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on Sunpointe's 13F filing for Q1 2026, filed 21 Apr 2026.